Delving into the Latest Updates on TP53-EphA-2-CAR-DC vaccine(Chinese PLA General Hospital) with Synapse

Overview

Basic Info

Drug Type

CAR-DC

Synonyms-

Target

EphA2

Mechanism

EphA2 modulators(Ephrin type-A receptor 2 modulators), Dendritic cells modulators, Gene transference

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Chinese People's Liberation Army General Hospital

Active Organization

Zhejiang University

Chinese People's Liberation Army General Hospital

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of TP53-EphA-2-CAR-DC vaccine; detect T cell response against TP53 mutant peptide and tumor neoepitopes after the treatment with TP53-EphA-2-CAR-DC vaccine and ICIs.

Start Date04 Jul 2023

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

[+1]

100 Clinical Results associated with TP53-EphA-2-CAR-DC vaccine(Chinese PLA General Hospital)

Login to view more data

100 Translational Medicine associated with TP53-EphA-2-CAR-DC vaccine(Chinese PLA General Hospital)

Login to view more data

100 Patents (Medical) associated with TP53-EphA-2-CAR-DC vaccine(Chinese PLA General Hospital)

Login to view more data

100 Deals associated with TP53-EphA-2-CAR-DC vaccine(Chinese PLA General Hospital)

Login to view more data